Literature DB >> 12456883

Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel.

Limin Wang1, Hilal A Lashuel, Thomas Walz, Wilfredo Colon.   

Abstract

Serum amyloid A (SAA) is a small apolipoprotein that binds to high-density lipoproteins in the serum. Although SAA seems to play a role in host defense and lipid transport and metabolism, its specific functions have not been defined. Despite the growing implications that SAA plays a role in the pathology of various diseases, a high-resolution structure of SAA is lacking because of limited solubility in the high-density lipoprotein-free form. In this study, complementary methods including glutaraldehyde cross-linking, size-exclusion chromatography, and sedimentation-velocity analytical ultracentrifugation were used to show that murine SAA2.2 in aqueous solution exists in a monomer-hexamer equilibrium. Electron microscopy of hexameric SAA2.2 revealed that the subunits are arranged in a ring forming a putative central channel. Limited trypsin proteolysis and mass spectrometry analysis identified a significantly protease-resistant SAA2.2 region comprising residues 39-86. The isolated 39-86 SAA2.2 fragment did not hexamerize, suggesting that part of the N terminus is involved in SAA2.2 hexamer formation. Circular-dichroism spectrum deconvolution and secondary-structure prediction suggest that SAA2.2 contains approximately 50% of its residues in alpha-helical conformation and <10% in beta-structure. These findings are consistent with the recent discovery that human SAA1.1 forms a membrane channel and have important implications for understanding the 3D structure, multiple functions, and pathological roles of this highly conserved protein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12456883      PMCID: PMC138545          DOI: 10.1073/pnas.252508399

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

Review 1.  Serum amyloid A, the major vertebrate acute-phase reactant.

Authors:  C M Uhlar; A S Whitehead
Journal:  Eur J Biochem       Date:  1999-10

2.  Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2.

Authors:  J Sipe
Journal:  Amyloid       Date:  1999-03       Impact factor: 7.141

3.  Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.

Authors:  J D Gillmore; L B Lovat; M R Persey; M B Pepys; P N Hawkins
Journal:  Lancet       Date:  2001-07-07       Impact factor: 79.321

4.  Expression of mouse apolipoprotein SAA1.1 in CE/J mice: isoform-specific effects on amyloidogenesis.

Authors:  J Yu; H Zhu; J T Guo; F C de Beer; M S Kindy
Journal:  Lab Invest       Date:  2000-12       Impact factor: 5.662

5.  Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set.

Authors:  N Sreerama; R W Woody
Journal:  Anal Biochem       Date:  2000-12-15       Impact factor: 3.365

Review 6.  Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states.

Authors:  S Urieli-Shoval; R P Linke; Y Matzner
Journal:  Curr Opin Hematol       Date:  2000-01       Impact factor: 3.284

7.  Adhesion of human platelets to serum amyloid A.

Authors:  Simcha Urieli-Shoval; George Shubinsky; Reinhold P Linke; Mati Fridkin; Israel Tabi; Yaacov Matzner
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

8.  The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis.

Authors:  J B Ancsin; R Kisilevsky
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

9.  Mapping of antigenic determinants of purified, lipid-free human serum amyloid A proteins.

Authors:  E Malle; R Herz; A Artl; A Ibovnik; F Andreae; W Sattler
Journal:  Scand J Immunol       Date:  1998-11       Impact factor: 3.487

10.  A unique amyloidogenic apolipoprotein serum amyloid A (apoSAA) isoform expressed by the amyloid resistant CE/J mouse strain exhibits higher affinity for macrophages than apoSAA1 and apoSAA2 expressed by amyloid susceptible CBA/J mice.

Authors:  J Liang; R Elliott-Bryant; T Hajri; J D Sipe; E S Cathcart
Journal:  Biochim Biophys Acta       Date:  1998-10-02
View more
  23 in total

1.  Inflammation protein SAA2.2 spontaneously forms marginally stable amyloid fibrils at physiological temperature.

Authors:  Zhuqiu Ye; Diane Bayron Poueymiroy; J Javier Aguilera; Saipraveen Srinivasan; Yun Wang; Louise C Serpell; Wilfredo Colón
Journal:  Biochemistry       Date:  2011-10-05       Impact factor: 3.162

Review 2.  Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution.

Authors:  Massimo Stefani; Christopher M Dobson
Journal:  J Mol Med (Berl)       Date:  2003-08-27       Impact factor: 4.599

3.  Influence of the carboxy terminus of serum amyloid A on protein oligomerization, misfolding, and fibril formation.

Authors:  Sanket Patke; Ronak Maheshwari; Jeffrey Litt; Saipraveen Srinivasan; J Javier Aguilera; Wilfredo Colón; Ravi S Kane
Journal:  Biochemistry       Date:  2012-03-26       Impact factor: 3.162

4.  Urea-induced denaturation of apolipoprotein serum amyloid A reveals marginal stability of hexamer.

Authors:  Limin Wang; Wilfredo Colón
Journal:  Protein Sci       Date:  2005-06-03       Impact factor: 6.725

Review 5.  Amyloid peptide channels.

Authors:  B L Kagan; R Azimov; R Azimova
Journal:  J Membr Biol       Date:  2004-11       Impact factor: 1.843

6.  Serum amyloid A 2.2 refolds into a octameric oligomer that slowly converts to a more stable hexamer.

Authors:  Yun Wang; Saipraveen Srinivasan; Zhuqiu Ye; J Javier Aguilera; Maria M Lopez; Wilfredo Colón
Journal:  Biochem Biophys Res Commun       Date:  2011-03-31       Impact factor: 3.575

7.  Endothelial injury markers before and after nasal continuous positive airway pressure treatment for obstructive sleep apnoea hypopnoea syndrome.

Authors:  Maria Wilczynska; Samuel Rice; Gareth Davies; Keir E Lewis
Journal:  Sleep Breath       Date:  2013-12-11       Impact factor: 2.816

8.  Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2.

Authors:  Saipraveen Srinivasan; Sanket Patke; Yun Wang; Zhuqiu Ye; Jeffrey Litt; Sunit K Srivastava; Maria M Lopez; Dmitry Kurouski; Igor K Lednev; Ravi S Kane; Wilfredo Colón
Journal:  J Biol Chem       Date:  2012-12-05       Impact factor: 5.157

9.  Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils.

Authors:  Christopher G Adda; Vince J Murphy; Margaret Sunde; Lynne J Waddington; Jesse Schloegel; Gert H Talbo; Kleo Vingas; Vivian Kienzle; Rosella Masciantonio; Geoffrey J Howlett; Anthony N Hodder; Michael Foley; Robin F Anders
Journal:  Mol Biochem Parasitol       Date:  2009-04-09       Impact factor: 1.759

10.  Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A.

Authors:  J Javier Aguilera; Fuming Zhang; Julie M Beaudet; Robert J Linhardt; Wilfredo Colón
Journal:  Biochimie       Date:  2014-05-28       Impact factor: 4.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.